Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR7 | Q9NYK1 | 1/20 | 0.52 |
| ▸ | HTR3A | P46098 | 1/20 | 0.51 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.46 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.46 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.46 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.46 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.44 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.44 |
| ▸ | LSS | P48449 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4198059 | 0.82 | LSS (0.50) | CHRNA7CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL5020201 | 0.76 | ALDH1A1 (0.51) | CHRNA7PDE3BPDE3APDE10A | |
| SCHEMBL4649974 | 0.76 | CHRM2 (0.43) | TLR7CHRNA7CHRM2CHRM4CHRM5 | |
| SCHEMBL4649235 | 0.76 | CHRM2 (0.43) | TLR7CHRNA7CHRM2CHRM4CHRM5 | |
| SCHEMBL4674252 | 0.71 | PDE3B (0.47) | CHRNA7PDE3BPDE3APDE10A | |
| SCHEMBL5390772 | 0.71 | LSS (0.60) | CHRNA7LSS | |
| SCHEMBL3218495 | 0.71 | LSS (0.56) | CHRNA7CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL3218661 | 0.71 | LSS (0.56) | CHRNA7CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL3218491 | 0.71 | LSS (0.56) | CHRNA7CHRM2CHRM4CHRM5CHRM1 | |
| SCHEMBL9469306 | 0.71 | LSS (0.57) | CHRNA7CHRM2CHRM1CHRM3LSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090005390-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND THEIR USE | NEUROSEARCH A/S | 2009-01-01 | — | — | US | claimed |
| US-20050245567-A1 | Novel quinuclidine derivatives and their use | NEUROSEARCH A/S (DK) | 2005-11-03 | — | — | US | claimed |
| EP-1532144-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND THEIR USE | NEUROSEARCH A/S (DK) | 2005-05-25 | — | — | EP | claimed |
| WO-2004016608-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND THEIR USE | NEUROSEARCH A/S (DK) | 2004-02-26 | — | — | WO | claimed |
| US-20090005390-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND THEIR USE | NEUROSEARCH A/S | 2009-01-01 | — | — | US | disclosed |
| EP-1905771-A2 | Quinuclidine derivatives and their use | NeuroSearch A/S (DK) | 2008-04-02 | — | — | EP | disclosed |
| US-20050245567-A1 | Novel quinuclidine derivatives and their use | NEUROSEARCH A/S (DK) | 2005-11-03 | — | — | US | disclosed |
| EP-1532144-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND THEIR USE | NEUROSEARCH A/S (DK) | 2005-05-25 | — | — | EP | disclosed |
| WO-2004016608-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND THEIR USE | NEUROSEARCH A/S (DK) | 2004-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090005390-A1 | NOVEL QUINUCLIDINE DERIVATIVES AND THEIR USE | ACHE, CHRNA5, CHRNA3 | TLR7 830/4885HTR3A 120/4885CHRNA7 9/4885 |
| US-20050245567-A1 | Novel quinuclidine derivatives and their use | ACHE, CHRNA5, CHRNA3 | TLR7 830/4885HTR3A 120/4885CHRNA7 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.